We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01382901
Recruitment Status : Completed
First Posted : June 27, 2011
Results First Posted : June 27, 2011
Last Update Posted : February 20, 2018
Information provided by:
Luitpold Pharmaceuticals

Brief Summary:
The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

Condition or disease Intervention/treatment Phase
Restless Legs Syndrome (RLS) Drug: Ferric Carboxymaltose (FCM) Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
Study Start Date : March 2006
Primary Completion Date : July 2007
Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron Restless Legs
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Intravenous (IV) Iron Drug: Ferric Carboxymaltose (FCM)
Other Name: VIT-45
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. International Restless Legs Syndrome (IRLS) Total Score [ Time Frame: Change from Baseline to Day 28 ]
    The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects > or = to 18 years old, and able to give informed consent to the study.
  • RLS signs and symptoms affirming diagnosis. The IRLS Diagnostic Criteria for RLS must be met.
  • Subjects have RLS symptoms > or = to 5 nights per week for at least the past 3 months.
  • A baseline score > or = to 15 on the IRLS Rating Scale.
  • At least one leg with an average baseline Periodic Leg Movement while asleep (PLMS) > or = to 15 movements per hour and at least 3 days of baseline PLMS data is measurable in each leg.
  • Subjects on anti-depressants, sleep medications, dopamine agonists, benzodiazepines, narcotics or other RLS treatments must be off therapy at least one week or 5 half lives, whichever is longer before any baseline RLS assessments and PLM measurements are obtained.
  • Subject has regular sleep hours between 9 p.m. and 9 a.m.
  • Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control.

Exclusion Criteria:

  • RLS 2° to other CNS disease or injury. Such disorders include peripheral neuropathy, neurodegenerative disorders, and multiple sclerosis.
  • RLS 2° to Chronic Kidney Disease.
  • Any pain related or sleep related disorders (e.g. sleep apnea) which may confound the outcome measures.
  • History of neuroleptic akathisia.
  • Oral iron use (including multivitamins with iron) after screening.
  • Parenteral iron use within 4 weeks prior to screening.
  • Parenteral iron use > 125 mg per week within 4 to 8 weeks prior to screening.
  • History of > or = to 10 blood transfusions in the past 2 years.
  • Anticipated need for blood transfusion during the study.
  • Known hypersensitivity reaction to any component to FCM.
  • Previously participated in an FCM clinical trial.
  • Chronic or serious active severe infection.
  • Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for > 5 years).
  • Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
  • Receiving prescription medication for the treatment of bronchospasm.
  • Pregnant or lactating women.
  • Severe peripheral vascular disease with significant skin changes.
  • Seizure disorder currently being treated with medication.
  • Baseline ferritin > 300 ng/mL.
  • Baseline TSAT > or = to 45%.
  • History of hemochromatosis or hemosiderosis or other iron storage disorders.
  • AST or ALT greater than the upper limit of normal.
  • Hemoglobin greater than the upper limit of normal.
  • Calcium or phosphorous outside the normal range.
  • Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis.
  • Known positive HIV-1/HIV-2 antibodies (anti-HIV).
  • Received an investigational drug within 30 days before randomization.
  • Chronic alcohol or drug abuse within the past 6 months.
  • Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) III or IV, or poorly controlled hypertension according to the judgment of the investigator.
  • Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
  • Subject unable to comply with study requirements.

ClinicalTrials.gov Identifier: NCT01382901     History of Changes
Other Study ID Numbers: 1VIT05009
First Posted: June 27, 2011    Key Record Dates
Results First Posted: June 27, 2011
Last Update Posted: February 20, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Psychomotor Agitation
Restless Legs Syndrome
Pathologic Processes
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders
Trace Elements
Growth Substances
Physiological Effects of Drugs